Search

everythinglearnresearchcommunity

for

Search:↓

Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The user is frustrated with hair loss, having switched from topical minoxidil and finasteride to dutasteride and oral minoxidil without seeing improvements. They are considering a hair transplant and are advised to continue the current treatment and explore therapy or lifestyle changes.

The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.

Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

A 39 year old female who has been taking finasteride for 1.5 months and is experiencing side effects such as muscle and butt shrinkage, and weight loss despite still having tight clothing. The user is seeking advice from those with knowledge of bodybuilding and hormones to help figure out the issue.

Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.

Creatine does not cause hair loss, but it may accelerate it in those predisposed to male pattern baldness. The study suggests that creatine does not affect DHT or hair loss, but individual reactions may vary.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

The user feels hopeless about hair loss despite using finasteride, dutasteride, minoxidil, and RU58841, and having a hair transplant. They are advised to maintain consistency in treatment, consider increasing dutasteride dosage, and explore topical solutions for better results.

Creatine may increase DHT levels, potentially affecting hair loss, but experiences vary. Many users use finasteride to counteract potential effects.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

A 22-year-old is using dutasteride 0.5mg daily, oral minoxidil 2.5mg, biotin 5mg, and microneedling for hair loss. They also use a shampoo with saw palmetto and green coffee but are unsure of its effectiveness due to its high cost.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

The conversation discusses concerns about Dr. Rassman's topical Finasteride, specifically whether it is liposomal or glycol-based. Dr. Rassman insists on providing the correct liposomal formulation and urges patients to contact him if they receive the wrong product.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

The conversation is about finding places in the U.S. that offer dutasteride mesotherapy for hair loss. The user is seeking recommendations and success stories.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The conversation discusses using azelaic acid to reduce scalp inflammation while using RU58841 for hair loss. It suggests applying azelaic acid in the morning and RU58841 at night to avoid degradation, while also using dutasteride and minoxidil.

User started Finasteride for hair loss, combining it with Saw Palmetto, Fenugreek seeds, almonds, bananas, eggs, and a coconut-castor oil mixture. Early updates show initial shedding and tiny new hair growth at the temples.

The user was diagnosed with DUPA and initially treated with finasteride, then switched to dutasteride which worsened their hair loss. They are now returning to finasteride and adding treatments including oral minoxidil, Proscar, Viviscal, pumpkin seed oil, LLLT, and Nizoral shampoo, hoping for hair regrowth.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.